Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 27418 | 8.15 |
09:34 ET | 15711 | 8.03 |
09:36 ET | 800 | 8.1099 |
09:38 ET | 8912 | 8.2 |
09:39 ET | 27884 | 8.3 |
09:41 ET | 13075 | 8.29 |
09:43 ET | 4818 | 8.275 |
09:45 ET | 10650 | 8.27 |
09:48 ET | 5100 | 8.315 |
09:50 ET | 6864 | 8.25 |
09:52 ET | 2934 | 8.29 |
09:54 ET | 3675 | 8.305 |
09:56 ET | 7409 | 8.27 |
09:57 ET | 5378 | 8.16 |
09:59 ET | 5114 | 8.21 |
10:01 ET | 10750 | 8.32 |
10:03 ET | 750 | 8.29 |
10:06 ET | 6007 | 8.235 |
10:08 ET | 8942 | 8.31 |
10:10 ET | 9491 | 8.3464 |
10:12 ET | 1809 | 8.23 |
10:14 ET | 2500 | 8.31 |
10:15 ET | 11444 | 8.22 |
10:17 ET | 6437 | 8.22 |
10:19 ET | 3258 | 8.24 |
10:21 ET | 3699 | 8.215 |
10:24 ET | 7851 | 8.225 |
10:26 ET | 3591 | 8.28 |
10:28 ET | 4649 | 8.23 |
10:30 ET | 6720 | 8.26 |
10:32 ET | 15410 | 8.37 |
10:33 ET | 14829 | 8.235 |
10:35 ET | 6527 | 8.265 |
10:37 ET | 200 | 8.28 |
10:39 ET | 15491 | 8.2931 |
10:42 ET | 1600 | 8.3152 |
10:44 ET | 4209 | 8.26 |
10:46 ET | 3800 | 8.285 |
10:48 ET | 200 | 8.285 |
10:50 ET | 2507 | 8.305 |
10:51 ET | 2622 | 8.3298 |
10:53 ET | 10221 | 8.3605 |
10:55 ET | 9181 | 8.363 |
10:57 ET | 4153 | 8.335 |
11:00 ET | 4340 | 8.295 |
11:02 ET | 6273 | 8.36 |
11:04 ET | 23633 | 8.468 |
11:06 ET | 23794 | 8.4 |
11:08 ET | 8969 | 8.38 |
11:09 ET | 15127 | 8.37 |
11:11 ET | 11053 | 8.4 |
11:13 ET | 12234 | 8.35 |
11:15 ET | 9264 | 8.28 |
11:18 ET | 13297 | 8.29 |
11:20 ET | 28066 | 8.24 |
11:22 ET | 9206 | 8.24 |
11:24 ET | 10764 | 8.21 |
11:26 ET | 7132 | 8.22 |
11:27 ET | 12788 | 8.23 |
11:29 ET | 3089 | 8.26 |
11:31 ET | 2089 | 8.255 |
11:33 ET | 2661 | 8.27 |
11:36 ET | 1600 | 8.22 |
11:38 ET | 4578 | 8.235 |
11:40 ET | 1291 | 8.25 |
11:42 ET | 1078 | 8.2393 |
11:44 ET | 1902 | 8.24 |
11:45 ET | 3931 | 8.24 |
11:47 ET | 1766 | 8.24 |
11:49 ET | 11722 | 8.29 |
11:51 ET | 995 | 8.26 |
11:54 ET | 2175 | 8.27 |
11:56 ET | 5416 | 8.31 |
11:58 ET | 3600 | 8.3 |
12:00 ET | 65339 | 8.22 |
12:02 ET | 23345 | 8.235 |
12:03 ET | 4041 | 8.18 |
12:05 ET | 5677 | 8.19 |
12:07 ET | 5284 | 8.196 |
12:09 ET | 1200 | 8.215 |
12:12 ET | 2031 | 8.2 |
12:14 ET | 1600 | 8.18 |
12:16 ET | 9081 | 8.21 |
12:18 ET | 5599 | 8.18 |
12:20 ET | 10339 | 8.115 |
12:21 ET | 4243 | 8.15 |
12:23 ET | 7717 | 8.1651 |
12:25 ET | 5857 | 8.16 |
12:27 ET | 6413 | 8.15 |
12:30 ET | 7969 | 8.13 |
12:32 ET | 2205 | 8.14 |
12:34 ET | 2636 | 8.16 |
12:36 ET | 3023 | 8.19 |
12:38 ET | 1400 | 8.185 |
12:39 ET | 7667 | 8.2 |
12:41 ET | 4411 | 8.17 |
12:43 ET | 2489 | 8.22 |
12:45 ET | 8541 | 8.22 |
12:48 ET | 2649 | 8.24 |
12:50 ET | 2829 | 8.26 |
12:52 ET | 8632 | 8.235 |
12:54 ET | 5761 | 8.215 |
12:56 ET | 1200 | 8.215 |
12:57 ET | 2481 | 8.215 |
12:59 ET | 2563 | 8.195 |
01:01 ET | 4949 | 8.23 |
01:03 ET | 2373 | 8.24 |
01:06 ET | 5016 | 8.245 |
01:08 ET | 1287 | 8.245 |
01:10 ET | 1808 | 8.23 |
01:12 ET | 1300 | 8.26 |
01:14 ET | 2407 | 8.24 |
01:15 ET | 1668 | 8.215 |
01:17 ET | 4382 | 8.2 |
01:19 ET | 5901 | 8.21 |
01:21 ET | 3461 | 8.19 |
01:24 ET | 733 | 8.23 |
01:26 ET | 15860 | 8.22 |
01:28 ET | 1891 | 8.25 |
01:30 ET | 3804 | 8.26 |
01:32 ET | 4396 | 8.245 |
01:33 ET | 1419 | 8.26 |
01:35 ET | 2959 | 8.26 |
01:37 ET | 4667 | 8.24 |
01:39 ET | 2606 | 8.25 |
01:42 ET | 2660 | 8.2599 |
01:44 ET | 3783 | 8.255 |
01:46 ET | 1700 | 8.27 |
01:48 ET | 4966 | 8.23 |
01:50 ET | 2404 | 8.24 |
01:51 ET | 3318 | 8.24 |
01:53 ET | 3552 | 8.23 |
01:55 ET | 2544 | 8.21 |
01:57 ET | 3969 | 8.23 |
02:00 ET | 5380 | 8.25 |
02:02 ET | 13595 | 8.22 |
02:04 ET | 2199 | 8.25 |
02:06 ET | 2612 | 8.23 |
02:08 ET | 6813 | 8.2299 |
02:09 ET | 2091 | 8.205 |
02:11 ET | 1925 | 8.2 |
02:13 ET | 2926 | 8.195 |
02:15 ET | 4394 | 8.21 |
02:18 ET | 3200 | 8.215 |
02:20 ET | 1923 | 8.17 |
02:22 ET | 3703 | 8.24 |
02:24 ET | 1003 | 8.24 |
02:26 ET | 5711 | 8.24 |
02:27 ET | 4847 | 8.21 |
02:29 ET | 5609 | 8.16 |
02:31 ET | 4494 | 8.19 |
02:33 ET | 5321 | 8.22 |
02:36 ET | 1150 | 8.24 |
02:38 ET | 2599 | 8.26 |
02:40 ET | 27140 | 8.17 |
02:42 ET | 1878 | 8.19 |
02:44 ET | 1318 | 8.21 |
02:45 ET | 2325 | 8.24 |
02:47 ET | 11381 | 8.22 |
02:49 ET | 3495 | 8.195 |
02:51 ET | 5701 | 8.22 |
02:54 ET | 1388 | 8.25 |
02:56 ET | 3545 | 8.26 |
02:58 ET | 12603 | 8.24 |
03:00 ET | 5611 | 8.25 |
03:02 ET | 10900 | 8.23 |
03:03 ET | 2324 | 8.215 |
03:05 ET | 1400 | 8.2 |
03:07 ET | 6867 | 8.21 |
03:09 ET | 3054 | 8.21 |
03:12 ET | 12300 | 8.165 |
03:14 ET | 2910 | 8.17 |
03:16 ET | 15482 | 8.12 |
03:18 ET | 8247 | 8.14 |
03:20 ET | 226 | 8.14 |
03:21 ET | 1100 | 8.135 |
03:23 ET | 1000 | 8.135 |
03:25 ET | 8215 | 8.12 |
03:27 ET | 11391 | 8.13 |
03:30 ET | 25861 | 8.1 |
03:32 ET | 6092 | 8.1 |
03:34 ET | 19368 | 8.11 |
03:36 ET | 11664 | 8.085 |
03:38 ET | 8558 | 8.08 |
03:39 ET | 6027 | 8.085 |
03:41 ET | 3494 | 8.055 |
03:43 ET | 10232 | 8.05 |
03:45 ET | 16608 | 8.085 |
03:48 ET | 5334 | 8.04 |
03:50 ET | 8669 | 8.039 |
03:52 ET | 8556 | 8.055 |
03:54 ET | 15493 | 8.075 |
03:56 ET | 27578 | 8.04 |
03:57 ET | 34662 | 8.095 |
03:59 ET | 242894 | 8.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.8B | -48.8x | --- |
Viking Therapeutics Inc | 5.8B | -56.0x | --- |
Madrigal Pharmaceuticals Inc | 6.1B | -12.0x | --- |
BridgeBio Pharma Inc | 5.4B | -9.0x | --- |
Cytokinetics Inc | 6.3B | -9.8x | --- |
Nuvalent Inc | 5.2B | -32.8x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.96 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -48.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.